TABLE 1.
Relative amounts of mRNAs in CVCs treated with LXR agonists
CVCs were treated with LXR agonists for 14 days, and the medium was changed every two days. Changes in gene expression are reported as ratios relative to the vehicle control (n = 6). Bold type indicates statistical significance (p < 0.05 vs. vehicle). Standard errors of the mean were omitted for clarity.
| Vehicle | GW3965 | GW3965 | T090 | T090 | |
|---|---|---|---|---|---|
| 0.3 μm | 3.0 μm | 0.3 μm | 3.0 μm | ||
| ABCA1 | 1.00 | 14.85 | 21.41 | 26.66 | 48.21 |
| ABCG1 | NDa | 52.45 | 141.73 | 210.34 | 275.05 |
| ALP | 1.00 | 1.32 | 1.94 | 1.81 | 3.43 |
| Msx2 | 1.00 | 0.85 | 1.28 | 1.28 | 1.46 |
| Runx2 | 1.00 | 0.84 | 0.85 | 0.86 | 0.90 |
| Osx | 1.00 | 1.09 | 1.07 | 1.12 | 1.29 |
| MGP | 1.00 | 0.19 | 0.21 | 0.18 | 0.07 |
| OCL | 1.00 | 0.43 | 0.47 | 0.25 | 0.09 |
| OPN | 1.00 | 0.52 | 0.31 | 0.39 | 0.18 |
| OPG | 1.00 | 0.88 | 0.82 | 1.09 | 1.85 |
| Pit1 | 1.00 | 1.05 | 1.64 | 1.34 | 2.20 |
| Pit2 | 1.00 | 0.92 | 1.03 | 1.01 | 1.20 |
| Tgm1 | 1.00 | 2.26 | 2.57 | 3.59 | 6.20 |
| Tgm2 | 1.00 | 1.20 | 1.33 | 1.41 | 12.34 |
| Tgm3 | 1.00 | 0.97 | 1.02 | 1.11 | 1.35 |
| Tgm5 | 1.00 | 1.34 | 3.19 | 6.43 | 18.18 |
| SREBP-1 | 1.00 | 2.98 | 3.77 | 3.26 | 7.59 |
| FAS | 1.00 | 2.15 | 2.63 | 1.83 | 3.99 |
| SCD-1 | 1.00 | 1.21 | 1.51 | 1.53 | 2.64 |
| ChREBP | 1.00 | 0.98 | 0.83 | 1.02 | 0.94 |
a Not detected—ABCG was not detectable in CVCs treated with the vehicle control.